Navellier & Associates’s NovoCure NVCR Stock Holding History

Navellier & Associates’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,875	Closed	-$497K	–	308
2020 Q4	$497K	Buy	+2,875	New	+$393K	0.09%	164

Other funds holding NVCR

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Navellier & Associates's NVCR Position: Q1 2021 in Review

Navellier & Associates sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 2,875 shares — an estimated $497K sold.

Navellier & Associates first reported a position in NVCR in Q4 2020 and held it in 1 quarter. The position peaked at $497K in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

Navellier & Associates reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
Navellier & Associates sold 2,875 NovoCure shares in Q1 2021, an estimated $497K.
Navellier & Associates first reported a position in NovoCure in Q4 2020 and held it in 1 quarter.
Navellier & Associates's NovoCure position peaked at $497K in Q4 2020.
327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Navellier & Associates's 13F filing for Q1 2021, filed 12 May 2021.